enGene Holdings Inc. (NASDAQ:ENGN) Given Average Rating of "Hold" by Brokerages

Key Points

• Analyst sentiment is neutral: enGene has a consensus “Hold” rating from 14 analysts, including eight holds, four buys and two sells. The average 12-month price target is $11.05.
• Shares remain under pressure: ENGN opened at $1.91, compared with a 52-week range of $1.40 to $12.25, while its 200-day moving average stands at $3.71.
• Quarterly results missed expectations: enGene reported a loss of $0.47 per share versus the $0.43-per-share consensus estimate, and analysts expect a full-year loss of $1.81 per share.

Shares of enGene Holdings Inc. (NASDAQ:ENGN - Get Free Report) have received a consensus recommendation of "Hold" from the fourteen analysts that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have assigned a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $11.0455.

ENGN has been the topic of several research analyst reports. HC Wainwright reiterated a "buy" rating and issued a $4.00 price objective on shares of enGene in a report on Tuesday, September 8th. Citizens Jmp reissued a "market perform" rating on shares of enGene in a report on Wednesday, September 9th. Weiss Ratings restated a "sell (e+)" rating on shares of enGene in a research report on Wednesday, August 12th. Citigroup reaffirmed a "market perform" rating on shares of enGene in a research note on Wednesday, September 9th. Finally, Wall Street Zen upgraded enGene from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 15th.

enGene Stock Performance

ENGN opened at $1.91 on Thursday. The company has a quick ratio of 10.21, a current ratio of 10.21 and a debt-to-equity ratio of 0.11. The company has a market cap of $127.95 million, a price-to-earnings ratio of -1.69 and a beta of -0.28. enGene has a 52-week low of $1.40 and a 52-week high of $12.25. The firm's fifty day simple moving average is $1.83 and its two-hundred day simple moving average is $3.71.

enGene (NASDAQ:ENGN - Get Free Report) last released its earnings results on Tuesday, September 8th. The company reported ($0.47) EPS for the quarter, missing analysts' consensus estimates of ($0.43) by ($0.04). Equities analysts anticipate that enGene will post -1.81 earnings per share for the current fiscal year.

Institutional Investors Weigh In On enGene

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP acquired a new stake in shares of enGene in the first quarter valued at about $251,000. Sei Investments Co. acquired a new position in enGene during the first quarter worth about $409,000. Renaissance Technologies LLC boosted its position in enGene by 651.1% during the first quarter. Renaissance Technologies LLC now owns 156,100 shares of the company's stock worth $1,063,000 after acquiring an additional 135,318 shares during the last quarter. SR One Capital Management LP acquired a new position in enGene during the second quarter worth about $1,293,607. Finally, Elmind Capital LP purchased a new stake in enGene during the 4th quarter valued at about $1,896,000. Institutional investors and hedge funds own 64.16% of the company's stock.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.